Abstract
Members of the ErbB receptor tyrosine kinase family are central regulators of several normal as well as tumor cell functions. A number of therapeutic compounds such as small molecular weight tyrosine kinase inhibitors and monoclonal antibodies have been developed to inhibit ErbB signaling in cancer. Drugs that target epidermal growth factor receptor (EGFR = ErbB1) and/or ErbB2 have demonstrated effect against breast, colorectal, lung, pancreatic and head and neck carcinomas, and are currently in clinical use. Part of the anti-tumor effect of the ErbB inhibitor drugs has been suggested to derive from inhibition of tumor angiogenesis. There are several proposed mechanisms by which the ErbB inhibiting agents may regulate tumor neovascularization although most of them are currently not fully characterized. This review addresses the role of ErbB signaling in angiogenesis, as well as the anti-angiogenic mechanisms of ErbB targeted cancer drugs.
Keywords: Anti-angiogenic drugs, cancer, EGFR, endothelial cells, HER, monoclonal antibodies, pericytes, smooth muscle cells, tyrosine kinase inhibitors
Current Vascular Pharmacology
Title: ErbB Targeted Drugs and Angiogenesis
Volume: 8 Issue: 3
Author(s): Erika Iivanainen and Klaus Elenius
Affiliation:
Keywords: Anti-angiogenic drugs, cancer, EGFR, endothelial cells, HER, monoclonal antibodies, pericytes, smooth muscle cells, tyrosine kinase inhibitors
Abstract: Members of the ErbB receptor tyrosine kinase family are central regulators of several normal as well as tumor cell functions. A number of therapeutic compounds such as small molecular weight tyrosine kinase inhibitors and monoclonal antibodies have been developed to inhibit ErbB signaling in cancer. Drugs that target epidermal growth factor receptor (EGFR = ErbB1) and/or ErbB2 have demonstrated effect against breast, colorectal, lung, pancreatic and head and neck carcinomas, and are currently in clinical use. Part of the anti-tumor effect of the ErbB inhibitor drugs has been suggested to derive from inhibition of tumor angiogenesis. There are several proposed mechanisms by which the ErbB inhibiting agents may regulate tumor neovascularization although most of them are currently not fully characterized. This review addresses the role of ErbB signaling in angiogenesis, as well as the anti-angiogenic mechanisms of ErbB targeted cancer drugs.
Export Options
About this article
Cite this article as:
Iivanainen Erika and Elenius Klaus, ErbB Targeted Drugs and Angiogenesis, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112241
DOI https://dx.doi.org/10.2174/157016110791112241 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting STAT1 in Both Cancer and Insulin Resistance Diseases
Current Protein & Peptide Science EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Targeting HOTAIR induces mitochondria related apoptosis and inhibits tumor growth in head and neck squamous cell carcinoma in vitro and in vivo.
Current Molecular Medicine Effect of Altered WIG-1 Expression on DDP Sensitivity in a DDPResistant Esophageal Squamous Cancer Cell Line
Current Cancer Drug Targets A Novel Small Molecule Inhibitor of FAK and IGF-1R Protein Interactions Decreases Growth of Human Esophageal Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA Interstitial Lung Disease in Idiopathic Inflammatory Myopathy
Current Rheumatology Reviews Platelet Biomarkers in Tumor Growth
Current Proteomics MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry DNA Instability at Chromosomal Fragile Sites in Cancer
Current Genomics Evaluation of Anticancer, Antibacterial and Antioxidant Properties of a Medicinally Treasured Fern Tectaria coadunata with its Phytoconstituents Analysis by HR-LCMS
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Current Chemical Biology Hypertension, Anti-Hypertensive Therapy and Neoplasia
Current Pharmaceutical Design